NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Will OpenText’s IBM-Trained New CEO Reframe Its AI Strategy and Competitive Edge (OTEX)?

On January 29, 2026, OpenText Corporation announced that Ayman Antoun will become Chief Executive Officer and join the Board on April 20, 2026, with James McGourlay moving from Interim CEO to an Executive Leadership Team role and P. Thomas Jenkins resuming the position of Chair of the Board. The appointment brings to OpenText a leader with decades of senior experience at IBM and current board roles at TD Bank and CAE, potentially influencing how the company steers its Enterprise Information...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness

What ACADIA Pharmaceuticals’ Recent Performance Tells You ACADIA Pharmaceuticals (ACAD) has drawn investor attention after a mixed stretch in the market, with the stock showing a 1 day return of about 2.2% decline and a 7 day move of roughly 6.4% decline. Over the past month the share price reflects about 5.9% decline, while the past 3 months show roughly 10.7% total return. This sets up an interesting backdrop for assessing the current US$25.13 price against the company’s fundamentals. See...
NYSE:AWK
NYSE:AWKWater Utilities

American Water Works Faces Rising Capital Demands And Regulated Growth Questions

Illinois American Water has submitted a sizeable rate request tied to pipeline replacements, infrastructure upgrades, lead service line removals, and PFAS treatment work planned over the next two years. Indiana American Water has started operating its first drinking water system focused on removing PFAS compounds. California American Water is investing in a large new groundwater well to support water supply reliability and system resiliency. These moves put American Water Works Company...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit Expands Ecosystem And Talent Pipeline As Shares Trade Below Targets

Intuit partnered with Checkr to integrate background checks into QuickBooks and HR tools for small and mid sized businesses. The company launched a Career Pipeline Program targeting skills development for one million accounting students. These steps expand Intuit's platform capabilities and support long term workforce development in the accounting field. For investors watching NasdaqGS:INTU, these updates come as the shares trade at $498.92. The stock has seen a 20.1% gain over three years...
NYSE:ASA
NYSE:ASACapital Markets

Assessing ASA Gold and Precious Metals (ASA) Valuation After Strong Earnings And Increased Saba Capital Ownership

ASA Gold and Precious Metals (ASA) has moved into focus after reporting full year 2025 results, with revenue of US$3.98 million and net income of US$664.07 million, alongside fresh buying from major shareholder Saba Capital Management. See our latest analysis for ASA Gold and Precious Metals. The latest results and Saba Capital's recent buying arrive after a sharp pullback, with a 1 day share price return of 10.4% decline and a 7 day return of 12.32% decline. However, the stock has shown...
NYSE:WTS
NYSE:WTSMachinery

A Look At Watts Water Technologies (WTS) Valuation After Recent Share Price Momentum

Watts Water Technologies (WTS) is back on many investors’ radar after recent share price moves, with the stock showing a 0.6% gain over the past day and 8.4% over the past month. See our latest analysis for Watts Water Technologies. That move comes on top of a 30 day share price return of 8.44% and a 90 day share price return of 9.80%. In addition, the 1 year total shareholder return of 45.90% and 5 year total shareholder return of 149.84% point to momentum that has been building over...
NasdaqGS:COLB
NasdaqGS:COLBBanks

Is Columbia Banking System (COLB) Still Attractive After Recent Multi‑Year Share Price Gains

Wondering if Columbia Banking System at around US$29.44 is offering good value right now, or if the easy gains are already behind it? The stock has recorded returns of 1.9% over the last 7 days, 5.3% over the past month, 4.4% year to date, 11.5% over 1 year and 46.4% over 5 years, which may catch the eye of investors thinking about growth potential or changing risk perceptions. Recent coverage of Columbia Banking System has focused on its position in the regional banking sector and how...
NasdaqGS:AGYS
NasdaqGS:AGYSSoftware

Does Agilysys’ (AGYS) Guidance Hike Reveal Durable Subscription Strength or One-Off Project Tailwinds?

In late January 2026, Agilysys reported record third-quarter fiscal 2026 results, with revenue of US$80.39 million and net income of US$9.9 million, while modestly raising its full-year revenue guidance to US$318 million. Beyond the headline numbers, the quarter underscored continued momentum in subscription and recurring revenue and progress on large hospitality projects such as its Marriott property management system deployment. With the company slightly upgrading its revenue outlook,...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities

Amgen (NasdaqGS:AMGN) is being sued over its decision to withdraw certain discounted drug prices from Sagebrush Health Services, a clinic serving underserved patients in California. The lawsuit claims Amgen’s actions unlawfully restricted access to lower cost medicines for economically challenged communities and may breach state law. Separately, Amgen has ended its collaboration with Kyowa Kirin on rocatinlimab, an investigational treatment for atopic dermatitis. The end of the rocatinlimab...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Is Affirm Holdings (AFRM) Price Justified After Recent Share Price Weakness?

If you are wondering whether Affirm Holdings at around US$60 a share still makes sense for your portfolio, the key question is how its current price lines up with underlying value. The stock has been volatile recently, with a 15.6% decline over the last 7 days, a 19.0% decline over 30 days, and an 18.5% decline year to date, even though the 3 year return sits at a very large gain and the 1 year return is a 1.3% decline. Recent headlines have focused on Affirm's position in the buy now, pay...
NasdaqGM:OLLI
NasdaqGM:OLLIMultiline Retail

Assessing Ollie’s Bargain Outlet Holdings (OLLI) Valuation After Rapid Store Expansion And Solid Same Store Sales

Why Ollie’s recent growth metrics are back in focus Ollie's Bargain Outlet Holdings (OLLI) is drawing fresh attention as investors react to its double-digit annual store growth and steady same-store sales gains. This has raised questions about how the company’s expansion is affecting the current share price. See our latest analysis for Ollie's Bargain Outlet Holdings. At a share price of $110.31, Ollie’s has seen a 2.84% 1 day share price gain. Its 90 day share price return of 8.69% and 1...
NasdaqGS:CORZ
NasdaqGS:CORZSoftware

Core Scientific Refocuses On HPC Leasing As Shareholders Block CoreWeave Deal

Core Scientific (NasdaqGS:CORZ) is shifting its focus from bitcoin mining to high performance computing leasing. The company plans to pursue more HPC colocation contracts starting in 2026. Shareholders recently rejected a proposed merger with CoreWeave, keeping Core Scientific independent. Core Scientific, trading at $17.99, is repositioning itself around HPC leasing while still carrying the legacy of its bitcoin mining roots. The stock has returned 23.6% over the past 30 days and 46.6%...
NYSE:PFE
NYSE:PFEPharmaceuticals

How Pfizer’s Novavax Matrix-M Deal and GIST Breakthrough (PFE) Has Changed Its Investment Story

In January 2026, Novavax announced a non-exclusive, worldwide license and option agreement granting Pfizer access to its Matrix-M adjuvant technology for vaccine development in up to two infectious disease areas, including an initial field already chosen and a US$30 million upfront payment this quarter. Together with FDA Breakthrough Therapy Designation for a gastrointestinal stromal tumor regimen combining Pfizer’s Sutent with bezuclastinib, these moves highlight Pfizer’s effort to deepen...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Assessing Applied Optoelectronics (AAOI) Valuation After Major 800G Transceiver Order And AI Data Center Momentum

Applied Optoelectronics (AAOI) has been in focus after securing a significant 800G transceiver order from a major hyperscale customer, along with positive commentary on its AI-focused laser products and the launch of a new high-powered pump laser. See our latest analysis for Applied Optoelectronics. Those AI centric product wins sit against a backdrop of sharp moves in the shares, with a 22.09% 7 day share price return and a 25.10% 30 day share price return. At the same time, the 1 year total...
NYSE:TJX
NYSE:TJXSpecialty Retail

TJX Companies (TJX) Valuation Check After Losing Streak And Strong Same Store Sales

TJX Companies (TJX) has just come off a seven day losing streak, with the stock declining 6.1% as retail sector headwinds and worries about a rich valuation weigh on recent trading. See our latest analysis for TJX Companies. Zooming out, TJX Companies has a 90 day share price return of 6.9% and a 1 year total shareholder return of 21.5%. Recent weakness therefore looks more like cooling momentum after a strong multi year run rather than a sharp change in how the market views its risk or...
NYSE:BKE
NYSE:BKESpecialty Retail

Assessing Buckle (BKE) Valuation After Recent Share Price Pullback And Undervaluation Signal

What Buckle’s Recent Performance Tells Current Shareholders Buckle (BKE) has drawn attention after a period where the share price shows an 11.5% decline over the past month and a 13.7% decline over the past 3 months, despite positive one year and multi year total returns. See our latest analysis for Buckle. At the current share price of $47.30, Buckle’s recent 7 day and 3 month share price declines sit against a stronger backdrop, with 1 year and 5 year total shareholder returns in...
NasdaqGS:CROX
NasdaqGS:CROXLuxury

How Crocs’ ‘Wonderfully Unordinary’ Global Campaign and Flagship Relaunch Will Impact Crocs (CROX) Investors

Crocs recently launched “Wonderfully Unordinary,” its first global omnichannel brand campaign since 2017, supported by a 90-second hero film and an extended roll-out through 2026 and beyond, while also unveiling a remodeled flagship store on New York City’s 34th Street. This marks a shift in Crocs’ branding toward themes of self‑expression and “becoming,” as it seeks a deeper connection with younger consumers through immersive retail and marketing experiences. With this renewed brand...
NYSE:DHI
NYSE:DHIConsumer Durables

D.R. Horton Uses Mortgage Incentives To Support Orders As Revenue Softens

D.R. Horton (NYSE:DHI) is using aggressive mortgage incentives and rate buydowns to support homebuyer demand in a challenging housing market. The company is combining these incentives with tight cost control as it reports a year over year revenue decline. Despite lower overall revenues, D.R. Horton reports growth in regional sales and resilient net sales orders, pointing to share gains in select markets. D.R. Horton, one of the largest U.S. homebuilders, is leaning on mortgage incentives...
NYSE:ARI
NYSE:ARIMortgage REITs

A Look At Apollo Commercial Real Estate Finance (ARI) Valuation After Recent Share Price Momentum

Event context and recent share performance Apollo Commercial Real Estate Finance (ARI) has drawn fresh attention after recent share price moves, with the stock showing a 1 day return of around a 1% decline and a 7 day gain of about 9%. Over the past month the stock has returned roughly 12%, while the past 3 months show a gain of about 10%. This has put recent trading action into focus for investors tracking listed commercial real estate lenders. See our latest analysis for Apollo Commercial...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors

In recent days, Apellis Pharmaceuticals reported strong momentum for its complement inhibitor Empaveli, including preliminary Q4 2025 U.S. net product revenue of about US$35.00 million, reflecting year-over-year growth and rapid uptake in treating paroxysmal nocturnal hemoglobinuria and other rare conditions with high unmet medical needs. Investor attention has also been drawn to analyst commentary highlighting Empaveli’s early market penetration and underappreciated commercial potential...
NasdaqGS:NFLX
NasdaqGS:NFLXEntertainment

Netflix All Cash Warner Bros. Discovery Bid Weighs Debt And Content Scale

Netflix has submitted an amended all cash bid to acquire Warner Bros. Discovery, shifting the structure of the proposed deal. The revised offer would increase Netflix's financial leverage and is drawing closer attention from regulators focused on competition in streaming and filmed entertainment. The move comes as investors assess how a larger content library and studio footprint might weigh against added debt and integration risks. Netflix, NasdaqGS:NFLX, is approaching this bid with its...
NasdaqGS:IPAR
NasdaqGS:IPARPersonal Products

Should Interparfums' (IPAR) Multi‑Decade Fragrance Licenses and $1.49 Billion Sales Require Investor Action?

In late January 2026, Interparfums, Inc. announced long-term, exclusive worldwide fragrance licenses for the Nautica and David Beckham brands, alongside a multi-decade extension of its GUESS fragrance agreement and reported 2025 net sales of US$1.49 billion. By locking in these licensing partnerships for up to 20 years and projecting tens of millions of dollars in annual Nautica and Beckham fragrance sales, Interparfums is deepening its pipeline of branded fragrance revenues well into the...
NasdaqCM:ASTH
NasdaqCM:ASTHHealthcare

Astrana Health (ASTH) Is Down 16.3% After Modest 2027 Medicare Advantage Update Proposal - What's Changed

Astrana Health recently came under pressure after the Centers for Medicare & Medicaid Services proposed only modest payment updates for Medicare Advantage in 2027, raising questions about future revenue tied to these plans. Analysts highlight that Astrana Health’s encounter-driven, risk-adjustment-focused care model could help limit the impact of these proposed policy changes while the company prepares to report its 2025 results in early March 2026. We’ll now look at how the Medicare...
NYSE:APH
NYSE:APHElectronic

Is It Too Late To Consider Amphenol (APH) After A 105% One-Year Rally?

If you are wondering whether Amphenol at around US$144 per share still offers value after a strong run, you are not alone. The stock has returned 6.6% over the past month, 3.1% year to date, 105.1% over the last year, 262.4% over three years, and 366.0% over five years, which can change how investors think about both its growth potential and its risk. Recent news coverage has focused on Amphenol's role as a major supplier of interconnect solutions across sectors like communications,...